TSCIP worked case · PDS0301

From a recurring evidence gap to a milestone-linked strategic outcome.

PDS0301 illustrates the public-facing TSCIP logic: synthesize the strategic uncertainty, define a decision-grade evidence path, and align development and capital with the next value inflection.

The strategic problem.

Within the TSCIP engagement, repeated de-identified strategic evaluations converged on a recurring issue: counterparties needed greater clarity on PDS0301's independent contribution to observed combination activity before underwriting a larger strategic commitment.

The TSCIP reframing

The recurring feedback was converted from a sequence of individual BD responses into a bounded evidence gate and a capital-to-inflection thesis.

The evidence-to-decision sequence.

1 · Synthesize the recurring requirement

The central contribution question was treated as a strategic decision requirement rather than a generic request for "more data."

2 · Define a bounded next step

The development path was reframed around a specific late-stage evidence milestone capable of changing the strategic discussion.

3 · Align capital with the inflection

The financing requirement was organized around reaching that milestone rather than simply extending operating runway.

4 · Re-enter the strategic process

The asset could then be discussed around a more explicit evidence, development and transaction thesis.

Separately verifiable public outcome.

August 11, 2026PDS Biotech publicly announced a strategic refocus prioritizing PDS0301 in metastatic colorectal cancer and a partnership strategy for PDS0101.
September 8, 2026PDS Biotech announced a PIPE led by Nant Capital with total potential proceeds initially described as up to $22.55 million, including a milestone closing tied to submission of a registrational Phase 3 protocol for PDS0301.
September 14, 2026PDS Biotech announced the initial closing, generating approximately $11.3 million in gross proceeds. The remaining milestone closing is $11 million, bringing total potential proceeds to approximately $22.3 million. Dr. Patrick Soon-Shiong and James Banaag joined the board, and NantWorks received a one-year exclusive right to negotiate an exclusive license to PDS0101.

Important distinction.

PDS Biotech's public announcements do not attribute the financing or board appointments to TSCIP. The description of TSCIP's role on this page reflects the TSCIP engagement and is presented to illustrate the TSCIP workflow. It should not be read as a claim that TSCIP was the sole cause of the financing or other publicly announced transactions.